| Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020) A Bhimraj, RL Morgan, AH Shumaker, V Lavergne, L Baden, VCC Cheng, ... Clinical Infectious Diseases 78 (7), e83-e102, 2024 | 1623* | 2024 |
| 2011 update of the drug resistance mutations in HIV-1 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ... Topics in antiviral medicine 19 (4), 156, 2016 | 1257 | 2016 |
| 2017 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 24 (4), 132, 2016 | 1247* | 2016 |
| The biological and clinical significance of emerging SARS-CoV-2 variants K Tao, PL Tzou, J Nouhin, RK Gupta, T de Oliveira, SL Kosakovsky Pond, ... Nature Reviews Genetics 22 (12), 757-773, 2021 | 1246 | 2021 |
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation International HIV Controllers Study Science 330 (6010), 1551-1557, 2010 | 1199 | 2010 |
| Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ... PloS one 4 (3), e4724, 2009 | 1188 | 2009 |
| Human immunodeficiency virus reverse transcriptase and protease sequence database SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer Nucleic acids research 31 (1), 298-303, 2003 | 1109 | 2003 |
| Web resources for HIV type 1 genotypic-resistance test interpretation TF Liu, RW Shafer Clinical infectious diseases 42 (11), 1608-1618, 2006 | 795 | 2006 |
| Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, ED Desmond, ... New England Journal of Medicine 328 (16), 1137-1144, 1993 | 791 | 1993 |
| Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer Genome research 17 (8), 1195-1201, 2007 | 574 | 2007 |
| HIV-1 antiretroviral resistance: scientific principles and clinical applications MW Tang, RW Shafer Drugs 72 (9), e1-e25, 2012 | 530 | 2012 |
| Rationale and uses of a public HIV drug‐resistance database RW Shafer The Journal of infectious diseases 194 (Supplement_1), S51-S58, 2006 | 517 | 2006 |
| HIV-1 drug resistance mutations: an updated framework for the second decade of HAART RW Shafer, JM Schapiro AIDS reviews 10 (2), 67, 2008 | 494 | 2008 |
| Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection GK Robbins, V De Gruttola, RW Shafer, LM Smeaton, SW Snyder, ... New England Journal of Medicine 349 (24), 2293-2303, 2003 | 490 | 2003 |
| Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection RW Shafer, DS Kim, JP Weiss, JM Quale Medicine 70 (6), 384-397, 1991 | 467 | 1991 |
| HIV-1 drug resistance and resistance testing DS Clutter, MR Jordan, S Bertagnolio, RW Shafer Infection, Genetics and Evolution 46, 292-307, 2016 | 445 | 2016 |
| HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ... Aids 21 (2), 215-223, 2007 | 444 | 2007 |
| Genotypic testing for human immunodeficiency virus type 1 drug resistance RW Shafer Clinical microbiology reviews 15 (2), 247-277, 2002 | 428 | 2002 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ... PLoS medicine 2 (4), e112, 2005 | 394 | 2005 |
| Genotypic predictors of human immunodeficiency virus type 1 drug resistance SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer Proceedings of the National Academy of Sciences 103 (46), 17355-17360, 2006 | 360 | 2006 |
